These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 9712083

  • 1. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis.
    Wendling D, Racadot E, Wijdenes J, Sibilia J, Flipo RM, Cantagrel A, Miossec P, Eschard JP, Macro M, Bertin P, Lioté F, Debiais F, Juvin R, Le Goff P, Masson C.
    J Rheumatol; 1998 Aug; 25(8):1457-61. PubMed ID: 9712083
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M.
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [Abstract] [Full Text] [Related]

  • 3. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
    Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, Jorgensen C, Keystone E, Levy R, Tesser J, Totoritis M, Truneh A, Weisman M, Wiesenhutter C, Yocum D, Zhu J.
    J Rheumatol; 2002 Feb; 29(2):220-9. PubMed ID: 11838838
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
    Lü LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, Li XF, Wu HX.
    Chin Med J (Engl); 2008 Apr 05; 121(7):615-9. PubMed ID: 18466681
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS.
    Arthritis Rheum; 2002 Dec 05; 46(12):3143-50. PubMed ID: 12483717
    [Abstract] [Full Text] [Related]

  • 6. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep 05; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 7. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
    Rau R, Sander O, van Riel P, van de Putte L, Hasler F, Zaug M, Kneer J, van der Auwera P, Stevens RM, Rheumatology Group 791.
    J Rheumatol; 2003 Apr 05; 30(4):680-90. PubMed ID: 12672184
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
    Gibofsky A, Rodrigues J, Fiechtner J, Berger M, Pan S.
    Clin Ther; 2007 Jun 05; 29(6):1071-85. PubMed ID: 17692722
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stamler DA.
    Arthritis Rheum; 2002 Aug 05; 46(8):2020-8. PubMed ID: 12209503
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M.
    Clin Ther; 2009 Aug 05; 31(8):1754-64. PubMed ID: 19808134
    [Abstract] [Full Text] [Related]

  • 11. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial.
    Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M, Fletcher MJ, Chasan-Taber S, Finger E, Morales A, Le CH, Trentham DE.
    Arthritis Rheum; 1998 Feb 05; 41(2):290-7. PubMed ID: 9485087
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis.
    Wendling D, Wijdenes J, Racadot E, Morel-Fourrier B.
    J Rheumatol; 1991 Mar 05; 18(3):325-7. PubMed ID: 1713269
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid arthritis.
    Zhang LL, Wei W, Xiao F, Xu JH, Bao CD, Ni LQ, Li XF.
    Arthritis Rheum; 2008 Jul 15; 59(7):905-10. PubMed ID: 18576295
    [Abstract] [Full Text] [Related]

  • 14. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
    Maksymowych WP, Blackburn WD, Tami JA, Shanahan WR.
    J Rheumatol; 2002 Mar 15; 29(3):447-53. PubMed ID: 11908555
    [Abstract] [Full Text] [Related]

  • 15. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan 15; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 16. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.
    Skov L, Kragballe K, Zachariae C, Obitz ER, Holm EA, Jemec GB, Sølvsten H, Ibsen HH, Knudsen L, Jensen P, Petersen JH, Menné T, Baadsgaard O.
    Arch Dermatol; 2003 Nov 15; 139(11):1433-9. PubMed ID: 14623703
    [Abstract] [Full Text] [Related]

  • 17. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug 15; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

  • 18. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms.
    Williams GW, Kivitz AJ, Brown MT, Verburg KM.
    Clin Ther; 2006 Feb 15; 28(2):204-21. PubMed ID: 16678642
    [Abstract] [Full Text] [Related]

  • 19. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
    Sokka T, Pincus T.
    J Rheumatol; 2003 Jun 15; 30(6):1138-46. PubMed ID: 12784382
    [Abstract] [Full Text] [Related]

  • 20. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.
    Wendling D, Racadot E, Wijdenes J.
    J Rheumatol; 1993 Feb 15; 20(2):259-62. PubMed ID: 8474061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.